Class IIITerminatedD-0001-2018
Drug recall · October 11, 2017
Deferoxamine Mesylate for injection recall
Why: CGMP Deviations: Firm failed to control impurity for color change at the API stage.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.
- Lots / codes
Lot: 51275DD; Exp. 09/01/17
- Quantity
- 32,276 10 mL vials
- Company
- Pfizer Inc., New York, NY
- Distribution
- Nationwide
- Initiated
- July 12, 2017 · Voluntary: Firm initiated
- Classified
- October 3, 2017
- Reported
- October 11, 2017
- Ended
- July 16, 2020
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.